Markets · 1 sources covering this

AstraZeneca Reports Mixed Lung Cancer Trial Results

AstraZeneca is stopping a clinical trial of the experimental drug volrustomig as it didn’t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where patients with non-small cell lung cancer received Tagrisso in combination with Orpathys. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·2h ago
AstraZeneca Reports Mixed Lung Cancer Trial Results
AstraZeneca is stopping a clinical trial of the experimental drug volrustomig as it didn’t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where patients with non-small cell lung cancer received Tagrisso in combination with Orpathys. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/22d007f5ed4c47b9356fc4c175faef7bbf353ed4"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="AstraZeneca Reports Mixed Lung Cancer Trial Results"></iframe>

AstraZeneca Reports Mixed Lung Cancer Trial Results

How 1 sources are covering this